Cipla’s acquisition of Avenue Therapeutics falls through. Here’s why

 Cipla’s acquisition of Avenue Therapeutics falls through. Here’s why
Indian drugmaker Cipla Ltd’s plan to fully acquire US-based Avenue Therapeutics Inc has fallen apart after the companies couldn’t complete the second stage of the transaction announced three years ago. Nasdaq-listed Avenue has served a notice of termination on Cipla unit InvaGen Pharmaceuticals Inc, the Indian company said Wednesday. “InvaGen […]
To read the rest of this article, you must be a subscriber. Click here to buy a subscription plan or Login here if you are already a subscriber.

Sumit Upadhyaya

error: Content is protected !!
The Capital Quest